SOPHiA GENETICS Secures Additional $25M Term Loan Commitments and Issues New Warrants

summarizeSummary

SOPHiA GENETICS SA secured an additional $25 million in term loan commitments and issued warrants for 275,000 ordinary shares, providing crucial capital but with potential future dilution.

check_boxKey Events

• Additional Term Loan Commitments

  The company secured an additional $25 million in term loan commitments from Perceptive Credit Holdings IV, LP, structured in two tranches (Tranche C and Tranche D).

• New Warrants Issued

  In connection with the loan amendment, SOPHiA GENETICS issued warrants for an additional 275,000 ordinary shares to the lender. 75,000 shares are immediately exercisable at $5.1829, with another 200,000 shares becoming exercisable upon drawdown of the new loan tranches at future VWAP-based prices.

• Loan Terms and Conditions

  The new term loans bear interest at Term SOFR + 6.25% and mature in 2029. The $12.5 million Tranche D loan is conditional on the company achieving over $85 million in trailing twelve-month revenue.

auto_awesomeAnalysis

SOPHiA GENETICS SA has amended its credit agreement with Perceptive Credit Holdings IV, LP, securing an additional $25 million in term loan commitments. This capital infusion is crucial for the company's liquidity and operations, providing a longer financial runway. However, the terms include a relatively high interest rate (Term SOFR + 6.25%) and the issuance of warrants for 275,000 ordinary shares, which represent potential future dilution for existing shareholders. The availability of one tranche is contingent on achieving a significant revenue milestone, indicating performance-based access to a portion of the funds. While the financing addresses immediate capital needs, the cost of debt and potential dilution are notable considerations for investors.